Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis.

Marlies WijsenbeekJeffrey J SwigrisYoshikazu InoueMichael KreuterToby M MaherTakafumi SudaMichael BaldwinHeiko MuellerKlaus B RohrKevin R Flahertynull null

Published in: The European respiratory journal (2024)

Based on changes in L-PF questionnaire scores, nintedanib reduced worsening of dyspnoea, fatigue and cough and the impacts of ILD over 52 weeks in patients with PPF.

Keyphrases

pulmonary fibrosis
interstitial lung disease
idiopathic pulmonary fibrosis
systemic sclerosis
sleep quality
rheumatoid arthritis
multiple sclerosis
cross sectional
psychometric properties
patient reported